Testing effectiveness (Phase 2)Ended earlyNCT03318939
What this trial is testing
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 648